The Phase II study (TACTI-002) in 1st line metastatic non-small cell lung carcinoma investigating
eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: updated results from a PD-L1
unselected population.
This is getting an oral presentation because of positive results.
Relatlimab got approval with a 25% increase in efficacy.
Earlier TACTI-002 results show eftilagimod doubled efficacy.
If updated results show this trend holds up we could see approval and sales within a year.
- Forums
- ASX - By Stock
- IMM
- Ann: Immutep to announce new TACTI-002 data at ASCO 2022
Ann: Immutep to announce new TACTI-002 data at ASCO 2022, page-15
-
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
29.0¢ |
Change
-0.010(3.33%) |
Mkt cap ! $421.2M |
Open | High | Low | Value | Volume |
30.0¢ | 30.0¢ | 28.5¢ | $751.3K | 2.589M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
21 | 307462 | 28.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.5¢ | 118494 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
20 | 257462 | 0.285 |
18 | 712543 | 0.280 |
6 | 125918 | 0.275 |
11 | 273188 | 0.270 |
7 | 124774 | 0.265 |
Price($) | Vol. | No. |
---|---|---|
0.295 | 118494 | 4 |
0.300 | 623600 | 3 |
0.305 | 191186 | 8 |
0.310 | 507281 | 6 |
0.315 | 138917 | 6 |
Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online